Humira approved for use in moderate Crohn's disease

The licensed indications for Humira (adalimumab) have been extended to include the treatment of adults with moderately active Crohn's disease, in addition to use in severe disease.

NICE guidance recommending adalimumab for use in severely active Crohn’s disease has been in place since 2010 | SCIENCE PHOTO LIBRARY
NICE guidance recommending adalimumab for use in severely active Crohn’s disease has been in place since 2010 | SCIENCE PHOTO LIBRARY

The TNF-alpha inhibitor should be used only when the response to conventional therapy, including a corticosteroid and/or an immunosuppressant, is inadequate or when such therapies are not tolerated or are contraindicated. 

View Humira drug record

Further information: AbbVie


Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New guidance for minimising psychological impact of COVID-19 pandemic in primary care patients
Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

MIMS launches Respiratory and Allergy Learning webinars

MIMS launches Respiratory and Allergy Learning webinars

Join us for the 2020 Respiratory and Allergy Learning...